Literature DB >> 13883049

Paroxysmal nocturnal haemoglobinuria: variation in clinical severity and association with bone-marrow hypoplasia.

J V DACIE, S M LEWIS.   

Abstract

Entities:  

Keywords:  BONE MARROW/diseases; HEMOGLOBINURIA, PAROXYSMAL/case reports

Mesh：

Year:  1961        PMID： 13883049     DOI： 10.1111/j.1365-2141.1961.tb00354.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  8 in total

1.  COURSE AND PROGNOSIS IN APLASTIC ANAEMIA.

Authors:  S M LEWIS
Journal:  Br Med J       Date:  1965-04-17

2.  Paroxysmal nocturnal haemoglobinuria.

Authors:  J V DACIE
Journal:  Proc R Soc Med       Date:  1963-07

Review 3.  Clinical manifestations of paroxysmal nocturnal hemoglobinuria: present state and future problems.

Authors:  Wendell F Rosse; Junichi Nishimura
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

Review 4.  Paroxysmal nocturnal hemoglobinuria and the glycosylphosphatidylinositol anchor.

Authors:  E T Yeh; W F Rosse
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

5.  Paroxysmal nocturnal haemoglobinuria.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1981-06-13

6.  Clinical paroxysmal nocturnal hemoglobinuria is the result of expansion of glycosyl-phosphatidyl-inositol-anchored protein-deficient clone in the condition of deficient hematopoiesis.

Authors:  K Pakdeesuwan; W Muangsup; Y U Pratya; S Issaragrisil; W Wanachiwanawin
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

7.  Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. I. The sensitivity of PNH red cells to lysis by complement and specific antibody.

Authors:  W F Rosse; J V Dacie
Journal:  J Clin Invest       Date:  1966-05       Impact factor: 14.808

Review 8.  Immune pathogenesis of paroxysmal nocturnal hemoglobinuria.

Authors:  Ramon Tiu; Jaroslaw Maciejewski
Journal:  Int J Hematol       Date:  2006-08       Impact factor: 2.490
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.